Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. A Southwest Oncology Group trial

Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1993-06, Vol.11 (2-3), p.227-229
Main Authors: Taylor, S A, Benedetti, J, Schuller, D, Richman, S P, Broun, G O, Hantel, A
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Anthraquinones - adverse effects
Anthraquinones - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Female
Head and Neck Neoplasms - drug therapy
Humans
Male
Middle Aged
Nausea - chemically induced
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Vomiting - chemically induced
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00874161